Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
-
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
-
Its acquiring biotech firms Curevo, LimmaTech Biologics, and the Vaccine Company,
-
Shares edged higher shortly after the opening bell.
https://www.cnbc.com/2026/05/26/eli-lilly-stock-vaccine-deals-curevo-limmatech.html